Celltrion Healthcare, the marketing arm of the biopharmaceutical company Celltrion won a huge deal in France last Friday (2nd November 2018) with big tenders for Herzuma, a biosimilar of Roche’s blockbuster breast cancer treatment Herceptin.
Herzuma, with indications for positive metastatic breast cancer, early cancer, and metastatic gastric cancer was launched in August after receiving approval from the European Commission in February.
Celltrion, the South Korea based company, secured deals with two procurement agencies that supply a major French hospital association. The order quantity equates to around 40 percent of the French Trastuzumab market — a huge win considering the position of the French pharma market as the third biggest in Europe.
Herzuma is the third biosimilar in Celltrion’s portfolio to receive European approval after Remsima, its version of pharma giants Johnson & Johnson’s Remicade and Truxima, a copy of Roche’s Rituxan.
